[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571277":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":49,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Resected HCC patients","EXPERIMENTAL","patients resected for HCC with NGS data, and paraffin material for immunohistochemistry analysis.",[13],"Diagnostic Test: Immunohistochemistry and in situ hybridisation analysis",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Immunohistochemistry and in situ hybridisation analysis","immunohistochemistry and in situ hybridisation analysis for several markers, including p53, beta-Catenin and albumin, but also markers considered diagnostic for HCC such as Glutamin Synthetase, Glypican-3 and HSP70, to identify a more rational diagnostic-prognostic algorithm for primary liver lesions.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Francesco Vasuri, MD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Francecso Vasuri, MD","CONTACT","0512143761","francesco.vasuri2@unibo.it",{"name":32,"role":28,"phone":29,"phoneExt":20,"email":33},"Deborah Malvi, MD","deborah.malvi@aosp.bo.it",[35],{"facility":5,"status":36,"city":37,"state":20,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Bologna","40138","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],11.33875,44.49381,{"lat":45,"lon":44},[48],{"name":32,"role":28,"phone":29,"phoneExt":20,"email":33},{"type":50,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100571277","immunohistochemical-algorithm-for-the-diagnosis-and-classification-of-hepatocellular-carcinomas-with-tert-tp53-and-ctnnb1-mutation-100571277",false,"NCT06718153","Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients resected for HCC\n* Availability of NGS data\n* Availability of paraffin material for immunohistochemistry investigations\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":60,"type":61},100,"ESTIMATED","INTERVENTIONAL",[64],"NA","The presence of certain mutations in HCC, such as TERT and TP53, have a suspected or proven prognostic role in resected patients, but lack a morphological or immunophenotypic counterpart, which would allow us to define which tumours are rationally candidate for molecular biology analysis. The identification of a histological and immunohistochemical algorithm to determine which HCCs to take to NGS for prognostic purposes will save time and economic costs in the laboratory by rationalising available resources. In the future, the application of the immunohistochemical and molecular algorithm on biopsy could allow better prognosis and predictivity even before surgery\u002Ftherapy.",[67,68],"Hepatic Cancer","Hepatic Resection",[70,71],"Molecular diagnostics","Immunohistochemistry","2024-12-04",{"date":74,"type":75},"2024-12-05","ACTUAL",{"date":77,"type":75},"2024-10-23",{"date":79,"type":61},"2025-06",{"name":5,"class":6},1]